Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819435) titled 'Phase 2/3 Efficacy and Safety of PP405 in Adult Males' on Sept. 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Pelage Pharmaceuticals, Inc.
Condition:
Androgenetic Alopecia
Intervention:
Drug: PP405 0.05% Topical Gel
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: September 2026
Target Sample Size: 600
To know more, visit https://clinicaltrials.gov/study/NCT07819435
Published by ...